Recent Updates
Recently added Catalysts

LTG-001

Phase 2

Acute Pain | Small molecule | Pain |Latigo Biotherapeutics, Inc.|Trials Updated: May 22, 2026

LTG-001 development status

Highest phase Phase 2
Registered trials 2 across 1 sponsor since Sep 2023

LTG-001 target and mechanism

Molecular targetNav1.8
Target classIon Channel
ModalitySmall molecule

Also known as Experimental: LTG-001 High Dose, LTG-001 High Dose

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials2
Total Enrollment593

FDA Designations

No designations recorded

LTG-001 clinical trials

LTG-001 · 2 trials · 3 indications

Phase 2 2
NCT07102459An Efficacy and Safety Study of LTG-001 Following AbdominoplastyAcute Pain
COMPLETED343 Analytics
NCT06774625This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsAcute Pain, Postoperative
COMPLETED250 Analytics
PHASE2COMPLETED
An Efficacy and Safety Study of LTG-001 Following Abdominoplasty
Acute Pain
NCT07102459343
Unlock trial analytics
PHASE2COMPLETED
This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars
Acute Pain, Postoperative
NCT06774625250
Unlock trial analytics

Study Endpoints

Primary Endpoints

SPIDr0-48
48 hours

Time-weighted SPIDr0-48 after the first dose of study drug.

SPID 0-12
12 hours

Pain Intensity NRS Score change over the study.

Secondary Endpoints

Total Opioid Rescue
48 hours
No Opioid requirement
48 hours
2-Point NPRS Reduction
48 hours
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LTG-001 High DoseEXPERIMENTALHigh Dose LTG-001
LTG-001 Low DoseEXPERIMENTAL -
HB/APAPACTIVE_COMPARATOR -
PlaceboPLACEBO_COMPARATOR -
LTG-001 Mid DoseEXPERIMENTALMedium Dose
SuzetrigineACTIVE_COMPARATORComparator

Interventions

NameTypeDescription
Experimental: LTG-001 High DoseDRUGHigh Dose Active
Experimental: LTG-001 Low DoseDRUGLower Dose Active
Active Comparator: HB/APAPDRUGActive Comparator
Placebo ComparatorDRUGPlacebo
LTG-001 High DoseDRUGLTG-001 High Dose
LTG-001 Mid DoseDRUGLTG-001 Mid Dose
LTG-001 Low DoseDRUGLTG-001 Low Dose
PlaceboOTHERPlacebo
SuzetrigineDRUGActive comparator - Nav1.8 inhibitor
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Subject is male or female aged 18 to 65 years * Scheduled to undergo an elective "partial" abdominoplasty under general anesthesia * Has a body BMI 18.0 to 35 kg/m2 * Has signed informed consent and will comply with the requirements and restrictions of the study * Meet lifesty...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Acute Kidney Injury 13 trials (matched to "Acute Pain")

Top 1 of 4 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN1PHASE2AZD4144
Unlock Competitive Intelligence

Other drugs targeting Nav1.8

VX-150 VRTX· PHASE2 VX-993 VRTX· PHASE2

Explore more on BiopharmaWatch

Latigo Biotherapeutics, Inc. (LTGO)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track